Influenza A Infections Epidemiology

DelveInsight's ‘Influenza A - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the United Kingdom
• Japan

Study Period: 2021-2034

Influenza A Disease Understanding

Influenza A Overview

Influenza virus affects the respiratory tract by a direct viral infection or damage from the immune system response. In humans, the respiratory epithelium is the only site where the hemagglutinin (HA) molecule is effectively cleaved, generating infectious virus particles. Virus transmission occurs through contact with aerosols or respiratory fomites from an infected individual. The inability of the lung to perform its primary function of gas exchange can result from multiple mechanisms, including obstruction of the airways, loss of alveolar structure, loss of lung epithelial integrity from direct epithelial cell killing, and degradation of the critical extracellular matrix.

Influenza A virus is the predominant viral etiology of acute respiratory distress syndrome (ARDS) in adults. Risk factors independently associated with ARDS are age between 36 and 55, pregnancy, and obesity, while protective factors are female sex, influenza vaccination, and infections with Influenza A (H3N2) or Influenza B viruses.

There are four types of influenza viruses: A, B, C, and D. Human influenza A and B viruses cause seasonal epidemics of disease (known as flu season) almost every winter in the United States. Influenza A viruses are the only viruses known to cause flu pandemics, i.e., global epidemics of flu disease. A pandemic can occur when a new and different influenza A virus infects people and can spread efficiently among people. Influenza C virus infections generally cause mild illness and are not thought to cause human epidemics. Influenza D viruses primarily affect cattle and are not known to infect or cause illness in people.

Influenza A Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total vaccinated pool of Influenza A, Influenza vaccine failure cases, total Influenza A positive cases, and strain-specific cases of Influenza A, in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2021 to 2034.

Key Findings

This section provides glimpse of the Influenza A epidemiology in the 7MM

Country Wise- Influenza A Epidemiology

The epidemiology segment also provides the Influenza A epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan

• The total vaccinated pool of Influenza A in the United States is approximately 176 million in 2021
• The total Influenza A positive cases in the United States comprised of 42,580 cases in 2021 and are projected to increase during the study period
• In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed 19, 7,405, 35,156 cases in 2021

Scope of the Report

• The report covers the descriptive overview of Influenza A, explaining its causes, signs and symptoms, pathogenesis and diagnosis
• Comprehensive insight has been provided into the Influenza A epidemiology and treatment
• The report provides insight about the historical and forecasted patient pool of Influenza A in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• A detailed review of Influenza A epidemiology forecast is included in the report, covering the 7MM drug outreach
• The report provides an edge while developing business strategies, by understanding epidemiological trends

Get a more detailed overview of How the Epstein–Barr Virus Market will evolve by 2034: Epstein–Barr Virus Market Outlook and Forecast

Report Highlights

• In the coming years, Influenza A market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, increase in incidence population
• As per DelveInsight’s analysis, the major types of Influenza include A, B, C, and D
• The report also encompasses other major segments, i.e., total vaccinated pool of Influenza A, Influenza vaccine failure cases, total Influenza A positive cases, and strain-specific cases of Influenza A

Influenza A Report Insights

• Patient Population
• Eleven Years Forecast
• 7MM Coverage
• Influenza A Epidemiology Segmentation

Key Questions

• What is the disease risk, burden and unmet needs of Influenza A?
• What is the historical Influenza A patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What would be the forecasted patient pool of Influenza A at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Influenza A?
• Out of the above-mentioned countries, which country would have the highest incident population of Influenza A during the study period (2021-2034)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2021-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Influenza A
• To understand the future market competition in the Influenza A market and Insightful review of the unmet needs.
• Quantify patient populations in the global Influenza A market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Influenza A in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
• The Influenza A epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources.